Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 24, 2009 Brian Orelli	Drugmakers' HIV Treatments Live On Companies that make HIV drugs could lose billions of dollars in revenue if an effective vaccine is developed. All drug-company investors need to keep an eye on up-and-coming drugs from competitors that could take market share.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
Chemistry World August 4, 2008 Pete Mitchell	Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate.
Chemistry World September 26, 2007 Victoria Gill	HIV Vaccines 'Will Not Work' Just days after US drug firm Merck revealed its leading HIV vaccine candidate had flopped in clinical trials, a leading immunologist has predicted that many other vaccines in the pipeline will also fail because their design is similarly flawed.
Chemistry World February 9, 2007 Victoria Gill	Africa's First Large-Scale HIV Vaccine Trial The first large-scale clinical trial of an HIV vaccine will involve around 3000 participants in five selected sites in South Africa. It will compare the effectiveness of the vaccine at reducing HIV infection compared to a placebo.
Chemistry World September 3, 2009 Sarah Houlton	New HIV vaccine hope A team of scientists in the US has discovered two new antibodies that could lead to an HIV vaccine.
Wired January 2003 Richard Martin	Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine.
The Motley Fool December 12, 2007 Brian Orelli	What's Merck Doing? With a nice solid pipeline Merck is on its way to its goal of double-digit EPS growth through 2010.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
The Motley Fool December 30, 2008 Brian Orelli	A Shot in the Arm for Novartis' Pipeline The company picks up the rights to a vaccine that fights a virus.
The Motley Fool October 16, 2007 Brian Orelli	Not a Blockbuster -- Yet Merck gains marketing approval for its newest HIV drug. Investors, take note.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
The Motley Fool January 21, 2010 Brian Orelli	Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really?
The Motley Fool July 25, 2007 Brian Orelli	Hopeful Flu Production Technology From Baxter While the clinical trial demonstrating strong immunogenicity for the new vaccine is certainly good news, the continued development of the production technology is probably the more important item for investors.
The Motley Fool March 18, 2008 Brian Orelli	Dynavax Gets Held Up The FDA puts a clinical hold on Dynavax Technologies hepatitis B vaccine. Investors, take note.
Fast Company August 8, 2011 Kate Rockwood	AIDS Vaccine Conference Despite billions in annual research dollars, the quest for an AIDS vaccine remains elusive.
The Motley Fool November 29, 2010 Brian Orelli	Head to Head: Merck vs. Itself Merck's HIV drug doesn't work as well when taken once daily.
AskMen.com	Vaccine Helps Prevent HIV For the first time, an experimental vaccine has prevented infection with the AIDS virus, a watershed event in the deadly epidemic and a surprising result.
BusinessWeek October 20, 2003 Gene G. Marcial	How Immune Response Targets AIDS Immune Response's Remune is aimed at slowing the advance of HIV and delaying the need for antiretroviral drugs, which have toxic effects. A look at the company's situation and its stock.
The Motley Fool July 19, 2010 Brian Orelli	Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so.
BusinessWeek September 2, 2010 Simeon Bennett	David Margolis' Fight to End AIDS The North Carolina professor is relying on Zolinza, a rarely used Merck cancer drug, to stamp out AIDS.
The Motley Fool November 19, 2009 Brian Orelli	Pfizer Dodges a Bullet The drugmaker slips through an advisory committee unscathed.
The Motley Fool April 6, 2010 Brian Orelli	Kill It! Double-Teaming Malaria Malaria vaccine might not make Glaxo and Crucell rich, but the life-saving and PR benefits would be welcome.
The Motley Fool February 23, 2010 Brian Orelli	The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu.
BusinessWeek February 19, 2007 Gene G. Marcial	Will Healthy Lab Data Revive Ailing Cell Genesys? Cell genesys is in the midst of clinical trials of vaccines for prostate and pancreatic cancer that analysts believe should catch investors' eyes.
Chemistry World January 19, 2015 Maria Burke	Roadmap to fast track Ebola vaccine development A global group of experts has developed a 'roadmap' to help the health community fast track an Ebola vaccine.
The Motley Fool May 8, 2009 Brian Orelli	Glaxo Goes Head-to-Head on HPV Glaxo's data may not be enough to help Cervarix knock Merck's Gardasil from the top papillomavirus vaccine spot.
The Motley Fool December 13, 2007 Brian Orelli	Merck's Vaccination Woes Merck announces it is recalling 1.2 million doses of a vaccine that immunizes children against Hib, which causes meningitis, pneumonia, and other serious infections.
Pharmaceutical Executive December 1, 2005 Alana Klein	Thought Leader: A Q&A with Graham Allaway While researchers continue to hunt for new AIDS drugs, Graham Allaway, chief operating officer of Panacos Pharmaceuticals, is focusing on developing a treatment for patients failing therapy due to resistance.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool March 24, 2011 Brian Orelli	It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool August 20, 2007 Brian Orelli	Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign.
The Motley Fool August 21, 2009 Brian Orelli	Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend.
The Motley Fool June 17, 2010 Luke Timmerman	Oncothyreon's Cancer Vaccine Back in the Saddle as Merck KGaA Re-Starts Clinical Trials The German-based Merck got clearance from the FDA and local ethics review boards to resume two of three large pivotal trials.
The Motley Fool July 1, 2008 Brian Lawler	FDA News Gives Glaxo a Glimmer of Hope Approval is delayed, but new studies won't be needed for Cervarix.
The Motley Fool October 23, 2007 Brian Orelli	Old Merck on New Drugs It looks like the old Merck is back, with new drugs driving double-digit sales growth in the third-quarter.
BusinessWeek January 9, 2006 Carol Matlack	Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine.
BusinessWeek October 22, 2007 Catherine Arnst	Roll Up Your Sleeve, Gramps A graying population may create a huge market for vaccines that buttress aging immune systems.
The Motley Fool May 31, 2006 Stephen D. Simpson	Vical Gets a Helping Hand Japan's AnGes MG's Allovectin-7 vaccine is now a risk-free lottery ticket for Vical. If phase 3 trials show adequate efficacy, there's upside. If the trials fail, Vical really doesn't lose much of anything. Investors, take note.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
The Motley Fool January 11, 2005 Charly Travers	The Future of Cancer Vaccines Biotech companies developing cancer vaccines have been in investors' doghouses for a long time. Can a vaccine help stave off forms of the disease?
Popular Mechanics September 2006 Ben Harder	Seeking Immunity Pathogens like West Nile virus show no respect for borders. But a new class of vaccines may soon keep them in check.
The Motley Fool December 4, 2006 Brian Lawler	Success for Dynavax Solid results from the first of three phase III trials cause the biopharmaceutical Dynavax's shares to rise.
Chemistry World August 5, 2015 Emma Stoye	Vaccine raises hopes of an end to Ebola A Phase III trial for a candidate Ebola vaccine has shown extremely encouraging results in Guinea, demonstrating complete protection for all those who were vaccinated.
The Motley Fool January 31, 2008 Brian Orelli	One Last Look at Pre-Enhance Merck Investors show they care more about Merck's future than its Q4 results.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
Chemistry World July 8, 2010 Sarah Houlton	Antibodies spark HIV vaccine hopes These cross-reactive broadly neutralising antibodies bound to and neutralised more than 90 per cent of the HIV strains they were tested against.
The Motley Fool March 8, 2010 Brian Orelli	Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting.